Inonotus obliquus mycelium IO12

Highly bioactive beta-glucans
 
Unique mushroom fermentation through patented technology!

What is Inonotus obliquus or chaga?

Chaga mushroom (Inonotus obliquus) is a fungus that grows mainly on the bark of birch trees in cold climates, such as northern Europe, Siberia and Russia.

This mushroom has long been used in Russia as a traditional remedy, mainly to promote immunity and overall health.

It is also used for the treatment of diabetes, to support cellular immunity and for heart disease.

Chaga contains the beta-glucan-rich polysaccharides that give medicinal mushroom powders their powerful immune-supporting properties. However, chaga also contains other active substances. Inotodiol and trametenolic acid are considered to be the most important bioactive compounds of the mushroom. These compounds exhibit various biological activities, including cell-regulating, anti-viral, hypoglycemic and antioxidant properties.

Chaga has a high ORAC score (measurement of antioxidant properties), comparable to that of blueberry extracts.


Why choosing Inonotus obliquus (chaga) through submerged fermentation?

Submerged cultivation is the best technology to manage the identity and purity of medicinal mushrooms without contamination. The bioactive substances of mushrooms are identified not only in the fruit body, but also in the mycelium culture and broth.

The most powerful ß -glucans are found in the mycelium, because the defence of the mushroom is most needed in the substrate. They are the so-called branched ß- 1,3-1,6 glucans.

After long and complex research, it has been possible to make liquid substrates for the different mushrooms where the mycelium can develop under ideal conditions. A sterile and liquid substrate is used where the mycelium is introduced and further develops for several weeks. When the mycelium is fully developed, everything is filtered. The filtration removes the not converted liquid substrate, but also the less active ß -glucans. Low-temperature membrane filtration with a molecular weight cut-off (MWCO) of 5,000 Da produces high-molecular ß-glucans that are highly bioactive. The filtrate containing the excreted beta-glucans, but also the mycelium is then freeze-dried.

This (expensive) technique guarantees optimal preservation of the triple helix structure of the ß -glucans, i.e. a biological activity that is not affected. The triple helix structure in most mushroom powders is largely damaged by heating and extraction using solvents.

Triple helix structure

Because we use a sterile substrate that allows the mycelium to develop in a sterile environment, the final product is also not bacterially contaminated. So extremely safe!

Inonotus obliquus mycelium IO12 shows a clear genetic similarity to fruiting bodies that grow naturally.

Image
Genetic similarities reach:
99.85%

Fermedics’ mushroom powders belong to the top of the world due to the advanced & unique production process in which a high concentration of active substances with an enormous stability and high efficiency is achieved.

Distinctive features

Unique properties of the production process

  • Produced by patented submerged fermentation
  • Subjected to low temperature membrane filtration technology
  • Reliable strain identification by DNA Sequence alignment (ITS1, 5.8 DNA, ITS2)
  • Very similar to wild type (WT) strain
  • Assessment of long-term storage
  • Active ingredient analyses and full safety assessment
  • High content of secondary metabolites and bioactive compounds
  • Bio-sustainability & environmentally friendly
  • Free of contaminants such as pesticides and heavy metals

 

What makes Inonotus obliquus mycelium IO12 so special?

  • Contains the most effective beta-glucans because of the:
    • preservation of the triple helix structure
    • very high absorbability due to water solubility
    • presence of high molecular weight extracellular beta-glucans
    • Specific branching (β-1,3 – β-1,6 glucans) which are more biologically active
  • Strong similarity to the wild variety through reliable strain identification
  • 100% pure polysaccharides and beta-glucans derived from the mycelium and extracellular excretion in the fermentation fluid
  • No risk of contamination (microbiological as well as chemical)
  • Relatively high amount of inotodiol and trametenolic acid due to submerged fermentation
  • 100 % pure powder
    • no heavy metal contamination
    • no pesticides/fungicides
    • no chemical additives
    • no extraction with solvents destroying triple helix structure
  • No functional starch derivatives, cyclodextrin, modified starches or other thickeners as additives
  • No traces of starch or cereals from the culture matrix or substrate.
  • No subsequent addition of polysaccharides.
More information

Health benefits

  • Antioxidative and anti-inflammatory properties
  • Cardiovascular support
  • Immune support
  • Improving glycaemic levels
  • Preventing abnormal pigmentation changes

Legislation

Europe
Inonotus obliquus is authorized in EU for use in food supplements.

Belgium
Inonotus obliquus is permitted in Belgium. This mushroom is listed in The Royal Decree of 29 August 1997 on the manufacture and trade of foodstuffs composed or containing plants or plant preparations.

Belfrit
Inonotus obliquus is on the Belfrit list and is allowed in Belgium, France and Italy.

Technical properties

Fermedics offers you on request all technical data of this ingredient, such as Certificate of Analysis (COA), and price quotation.

Storage
Due to the hygroscopic nature, please store at dry conditions in an airtight container. Shelf life is at least two years at 25°C and below 70% RH in original sealed package.

MOQ (minimum order quantity) 20 kg

FormUseDosageActive compounds
PowderNutritional supplements
Functional food
0,5 – 1,0 g/dayPolysaccharides > 12 %
β-glucans > 5 %
Inotodiol > 300 μg/g
Trametenolic acid > 500 μg/g

Would you like to receive more scientific info about Inonotus obliquus mycelium?

Yes please

References

  • Baek, J., Roh, H.-S., Baek, K.-H., Lee, S., Lee, S., Song, S.-S., and Kim, K.H. (2018). Bioactivity-based analysis and chemical characterization of cytotoxic constituents from Chaga mushroom (Inonotus obliquus) that induce apoptosis in human lung adenocarci noma cells. Journal of Ethnopharmacology 224, 63-75.
  • Cha, J.Y., Jun, B.S., Kim, J.W., Park, S.H., Lee, C.H., and Cho, Y.S. (2006). Hypoglycemic effects of fermented chaga mushroom (Inonotus obliquus) in the diabetic Otsuka Long-Evans Tokushima Fatty (OLETF) rat.
  • Glamočlija, J., Ćirić, A., Nikolić, M., Fernandes, A., Barros, L., Calhelha, R.C., Ferreira, I.C.F.R., Soković, M., and van Griensven, L.J.L.D. (2015). Chemical characterization and biological activity of Chaga (Inonotus obliquus), a medicinal “mushroom”. Journal of Ethnopharmacology 162, 323-332.
  • Nguyet, T.M.N., Lomunova, M., Le, B.V., Lee, J.S., Park, S.K., Kang, J.S., Kim, Y.H., and Hwang, I. (2018). The mast cell stabilizing activity of Chaga mushroom critical for its therapeutic effect on food allergy is derived from inotodiol. International Immuno pharmacology 54, 286-295.
  • Wang, J., Wang, C., Li, S., Li, W., Yuan, G., Pan, Y., and Chen, H. (2017). Anti-diabetic effects of Inonotus obliquus polysaccharides in streptozotocin-induced type 2 diabetic mice and potential mechanism via PI3K-Akt signal pathway. Biomedicine & Pharmacotherapy 95, 1669-1677.
  • Zhang, X., Bao, C., and Zhang, J. (2018). Inotodiol suppresses proliferation of breast cancer in rat model of type 2 diabetes mellitus via downregulation of ß-catenin signal ing. Biomedicine & Pharmacotherapy 99, 142-150.